Novartis AG

Novartis maintains a capital structure characterized by significant leverage, with long-term debt of $35.38 billion against total equity of $46.13 billion, resulting in a debt-to-equity ratio of 0.77. The balance sheet shows total assets of $110.95 billion and total liabilities of $64.82 billion. Liquidity is assessed as medium risk, supported by a current ratio of 1.12 and cash and equivalents of $8.86 billion. However, the company holds negative net cash after subtracting total debt from cash reserves, indicating a reliance on debt financing for operations and growth.

Profitability metrics demonstrate strong returns on capital, with a return on equity of 29.34% and a return on assets of 12.20%. The company generated $13.98 billion in net income on $56.33 billion in revenue, yielding a net margin of approximately 24.8%. Operating income stands at $17.54 billion, reflecting robust operational efficiency. While specific cohort medians are not provided for direct comparison, these return figures suggest high capital efficiency typical of mature pharmaceutical firms with strong patent portfolios.

Revenue concentration and geographic exposure details are not explicitly broken down in the available financial snapshot, but the company operates globally within the pharmaceutical industry. The absence of segment-specific revenue data in the current input prevents a detailed analysis of product mix or regional dependency, though the total revenue base of $56.33 billion indicates a large-scale operation.

Growth trajectory analysis is limited by the absence of historical period data in the current input. The latest normalized period shows revenue of $56.33 billion and net income of $13.98 billion. Without multi-year historical data, year-over-year growth rates cannot be calculated, but the substantial free cash flow of $6.99 billion suggests the company retains capacity for reinvestment or shareholder returns.

Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility in downturns. The dilution risk is low, as basic and diluted shares outstanding are identical at 19.08 billion, indicating no significant recent equity issuance or option dilution.

Recent market observations show a mean analyst price target of $124.43, significantly above the current market price of $82.90, suggesting potential upside according to consensus estimates. The mean recommendation is 2.54, with 4 strong buys, 8 buys, and 13 holds, indicating a cautiously optimistic sentiment among analysts. No specific filing, news, or transcript observations were provided in the input data.

Novartis AG (N1VS34.SA) experienced significant shifts in its shareholder registry during the period ending March 31, 2026, with the most material change involving investor ID 931. This entity dramatically increased its stake from 21,904 shares, valued at approximately $3.3 million, to 1,799,892 shares, representing a portfolio weight of 0.13% and a value of roughly $266.7 million. This substantial accumulation, detected in late June 2026, signals a major reallocation of capital into the Swiss pharmaceutical giant by this specific holder. Concurrently, the shareholder base expanded with the addition of three new notable investors as of the same March 31, 2026 reporting date. Investor ID 530 emerged as a significant new holder, acquiring 13,885,749 shares worth approximately $2.12 billion, which accounts for a 0.72% weight in the portfolio. Additionally, investor ID 930 added 532,554 shares valued at $81.4 million (0.019% weight), and investor ID 929 acquired 327,817 shares valued at $50.1 million (0.009% weight). These additions were all detected on June 20, 2026. Despite these notable movements in ownership structure, the company’s fundamental profile remains stable with no material changes reported against prior analysis across 17 reviewed fields. The broader institutional landscape continues to be defined by a base of 32 top holders and coverage from 16 analysts, suggesting that while specific large-scale transactions occurred, the overall consensus and structural metrics of the firm have not shifted materially. The influx of capital from investor ID 530, in particular, represents a substantial vote of confidence, given the $2.1 billion valuation of the new position. Combined with the aggressive buildup by investor ID 931, these changes highlight active interest from major institutional players in Novartis AG. For market observers, these registry updates underscore a period of concentrated accumulation among key stakeholders, even as the company’s operational and financial fundamentals remain unchanged.

Analysts project 63.7% upside to a mean price target of 124.43, significantly above the current market price of 76.00.

Free cash flow is projected to grow 37.1% year-over-year to 6.99 billion USD in fiscal year 2026.

Debt-to-equity ratio of 0.77 is below median, indicating higher leverage than the cohort median of 0.40.

The company faces medium liquidity risk, which could constrain financial flexibility during periods of market stress.

Long-term debt is projected to increase to 35.38 billion USD in fiscal 2026, up from 31.26 billion in 2025.

Capital expenditure as a percentage of revenue is below median, potentially signaling underinvestment in future growth drivers.

Revenue $13.51B, −0,5% YoY; Operating income −9,8% YoY.

• ▍Revenue $13.51B, −0,5% YoY
• ▍Operating income −9,8% YoY
• ▍Net income −12,5% YoY
• ▍Free cash flow −28,6% YoY
• ▍Net margin 23.4%

Revenue $13.86B, +2,2% YoY; Operating income +5,2% YoY.

• ▍Revenue $13.86B, +2,2% YoY
• ▍Operating income +5,2% YoY
• ▍Net income −14,5% YoY
• ▍Free cash flow −32,1% YoY
• ▍Net margin 17.4%

Revenue $14.36B, +9,0% YoY; Operating income +24,8% YoY.

• ▍Revenue $14.36B, +9,0% YoY
• ▍Operating income +24,8% YoY
• ▍Net income +23,2% YoY
• ▍Free cash flow +22,9% YoY
• ▍Net margin 27.4%

Revenue $14.53B, +12,9% YoY; Operating income +20,0% YoY.

• ▍Revenue $14.53B, +12,9% YoY
• ▍Operating income +20,0% YoY
• ▍Net income +24,5% YoY
• ▍Free cash flow +75,9% YoY
• ▍Net margin 27.8%

Revenue $13.59B; Operating income $4.63B.

• ▍Revenue $13.59B
• ▍Operating income $4.63B
• ▍Net margin 26.5%

Revenue $13.56B; Operating income $3.40B.

• ▍Revenue $13.56B
• ▍Operating income $3.40B
• ▍Net margin 20.8%

Revenue $13.17B; Operating income $3.60B.

• ▍Revenue $13.17B
• ▍Operating income $3.60B
• ▍Net margin 24.2%

Revenue $12.87B; Operating income $4.03B.

• ▍Revenue $12.87B
• ▍Operating income $4.03B
• ▍Net margin 25.2%

Revenue $56.33B, +8,9% YoY; Operating income +22,5% YoY.

• ▍Revenue $56.33B, +8,9% YoY
• ▍Operating income +22,5% YoY
• ▍Net income +17,1% YoY
• ▍Free cash flow +37,1% YoY
• ▍Net margin 24.8%

Revenue $51.72B, +10,8% YoY; Operating income +49,5% YoY.

• ▍Revenue $51.72B, +10,8% YoY
• ▍Operating income +49,5% YoY
• ▍Net income −19,6% YoY
• ▍Free cash flow +37,9% YoY
• ▍Net margin 23.1%

Revenue $46.66B, +7,6% YoY; Operating income +22,6% YoY.

• ▍Revenue $46.66B, +7,6% YoY
• ▍Operating income +22,6% YoY
• ▍Net income +113,5% YoY
• ▍Free cash flow +327,1% YoY
• ▍Net margin 31.8%

Revenue $43.38B, −1,4% YoY; Operating income −21,9% YoY.

• ▍Revenue $43.38B, −1,4% YoY
• ▍Operating income −21,9% YoY
• ▍Net income −71,0% YoY
• ▍Free cash flow −95,1% YoY
• ▍Net margin 16.0%